
HealthMore in Health→
ASCO Abstract Drop Signals a New Round in Oncology’s Data Race
Even with limited details in the supplied text, the release of regular ASCO abstracts appears to have focused attention on several contested oncology areas, underscoring how conference data now drives pharmaceutical deal
Key Takeaways
- ASCO’s abstract drop is highlighting several high-stakes oncology races.
- The supplied text points to interest in VEGF bispecifics, TROP2 ADCs and post-Ibrance strategies.
DE
DT Editorial Team··via endpoints.news
